HYPERGLYCOSYLATED HUMAN COAGULATION FACTOR IX

摘要

PROBLEM TO BE SOLVED: To provide an improved variant of human factor IX showing increased in vivo circulation half-life without a significant reduction of proteolytic activity or clot activity as compared to wild type human factor IX.SOLUTION: The invention provides a human coagulation factor IX polypeptide highly glycosylated having one or more mutation which causes an introduction of one or more glycosylation sites; and the method for preparing the polypeptide, a pharmaceutical composition comprising the polypeptide, and a treatment of not only hemophilia but diseases alleviated by the human coagulation factor IX.